-
Huapont Life Sciences Gains NMPA Approval for Generic Daivobet
•
China-based Huapont Life Sciences Co., Ltd (SHE: 002004) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of LEO Pharma’s Daivobet (calcipotriol, betamethasone). This approval marks the first generic version of Daivobet to be approved in China. Drug Composition and MechanismDaivobet…
-
Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets
•
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced a licensing agreement with Denmark-based LEO Pharma A/S, granting the dermatology specialist exclusive rights to store, distribute, promote, market, and sell its PD-1 inhibitor, toripalimab, in the European Union (EU), the European Economic Area (EEA), Switzerland, and the…
-
Gilead Sciences and LEO Pharma Alliance Targets Inflammatory Diseases
•
US-based major Gilead Sciences Inc. (NASDAQ: GILD) has formed a strategic alliance with Denmark-based dermatology specialist LEO Pharma A/S. The partnership aims to bolster the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs, targeting the potential treatment of patients with…
-
LEO Pharma’s Enstilar Outperforms Daivobet in Phase III Psoriasis Trial in China
•
Denmark-based dermatology specialist LEO Pharma A/S has announced positive outcomes for its drug candidate Enstilar (LEO 90100) in a Phase III clinical trial conducted in China. The trial focused on evaluating Enstilar as a potential treatment for Chinese patients with stable plaque psoriasis. The primary objective of the study was…
-
LEO Pharma Initiates Phase III Clinical Trial for Delgocitinib in China
•
Denmark-based LEO Pharma A/S has announced the commencement of a China Phase III clinical study with the enrollment and dosing of the first patient for its delgocitinib cream, marking the first clinical study for the product in China. This milestone signifies the company’s efforts to address moderate to severe adult…
